Acacia Pharma Group plc, a hospital pharmaceutical company, focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients in the United States and internationally.
The last earnings update was 35 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Acacia Pharma Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Acacia Pharma Group's
is considered below, and whether this is a fair price.
Price based on past earnings
Acacia Pharma Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
Acacia Pharma Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Acacia Pharma Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Acacia Pharma Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Acacia Pharma Group
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Acacia Pharma Group's finances.
The net worth of a company is the difference between its assets and liabilities.
Acacia Pharma Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Acacia Pharma Group's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Acacia Pharma Group's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Michael Bolinder, also known as Mike, has been Chief Executive Officer at Acacia Pharma Group plc since August 1, 2019 and its Director since August 2019. He served as the Chief Commercial Officer of Acacia Pharma Inc at Acacia Pharma Group plc until August, 2019. Mr. Bolinder joined Acacia Pharma in August 2015 as Vice President of Marketing. He has experience in the pharmaceutical industry. Prior to Acacia Pharma, he served as the Head of Marketing and Commercial Strategy for the Hospital Division at Mallinckrodt Pharmaceuticals (via the Cadence Pharmaceuticals, Inc. acquisition) which commercialised Ofirmev®, a post-operative pain control product promoted to anaesthetists and surgical teams. Prior to joining Cadence Pharmaceuticals, Inc., he worked at Eli Lilly and Company for years in various sales and marketing roles of increasing responsibility across multiple therapeutic areas and successful product launches. He earned his bachelor’s degree from Florida State University with double majors of International Business and Spanish.
Insufficient data for Mike to compare compensation growth.
Mike's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
Acacia Pharma Group
management team in years:
The average tenure for the Acacia Pharma Group management team is less than 2 years, this suggests a new team.
CEO & Director
Chief Financial Officer
Chief Medical Officer
Head of Project Leadership
Board of Directors Tenure
Average tenure and age of the
Acacia Pharma Group
board of directors in years:
The average tenure for the Acacia Pharma Group board of directors is less than 3 years, this suggests a new board.
Board of Directors
Independent Non-Executive Chairman
CEO & Director
Senior Independent Director
Independent Non-Executive Director
Pieter van der Meer
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Acacia Pharma Group plc, a hospital pharmaceutical company, focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients in the United States and internationally. The company’s lead product is BAREMSIS, an intravenous formulation of amisulpride that has completed Phase III clinical trials for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403 that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment. The company was founded in 2007 and is based in Cambridge, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.